2015
DOI: 10.1007/s11523-015-0383-8
|View full text |Cite
|
Sign up to set email alerts
|

Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study

Abstract: Background: Recently, in advanced non-small cell lung cancer (NSCLC), standard chemotherapy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
11
0

Year Published

2016
2016
2021
2021

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(11 citation statements)
references
References 32 publications
0
11
0
Order By: Relevance
“…However, we hypothesized that a higher but still unknown percentage of advanced non‐operable LC cases were histologically heterogeneous, consisting of NSCLC associated with an SCLC component, in comparison with surgically resected cancers where the rate of major histologic heterogeneity is only 4% for NSCLC and 9–26% for SCLC. If the hypothesis is correct, the therapeutic strategy should be able to target one of the components, leading to the selective growth of the other . Again, in the well‐known setting of oncogenic‐driven LC, several cases of mixed EGFR ‐mutated NSCLC/SCLC have been reported, suggesting a degree of plasticity between the two histotypes in some cases, without the selective pressure of TKIs.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…However, we hypothesized that a higher but still unknown percentage of advanced non‐operable LC cases were histologically heterogeneous, consisting of NSCLC associated with an SCLC component, in comparison with surgically resected cancers where the rate of major histologic heterogeneity is only 4% for NSCLC and 9–26% for SCLC. If the hypothesis is correct, the therapeutic strategy should be able to target one of the components, leading to the selective growth of the other . Again, in the well‐known setting of oncogenic‐driven LC, several cases of mixed EGFR ‐mutated NSCLC/SCLC have been reported, suggesting a degree of plasticity between the two histotypes in some cases, without the selective pressure of TKIs.…”
Section: Discussionmentioning
confidence: 99%
“…Usually, TKI resistance develops after an initial benefit through a variety of mechanisms. Among these, tumor histology changes are a mechanism of acquired resistance in EGFR‐mutated and ALK‐rearranged NSCLC cases . The availability of therapeutic approaches to overcome TKI resistance in oncogenic‐driven lung cancers (LCs) justifies secondary tumor biopsy in these patients …”
Section: Introductionmentioning
confidence: 99%
“…Genomic DNA was obtained from formalin-fixed paraffinembedded tissues after manual microdissection, for neoplastic cell enrichment (at least 50% of tumor cells), as previously reported [15]. Targeted next-generation sequencing analyses were performed in all samples using the Ion Torrent Personal Genome Machine (PGM, ThermoFisher Scientific), and an AmpliSeq custom panel targeting the entire coding sequence of 15 genes previously reported as adrenocortical carcinoma related: TP53, MSH2, MSH6, MLH1, PMS2, ATRX, DAXX, CTNNB1, MED12, MEN1, CTNNB1, PTCH1, APC, PTEN, ZNRF3.…”
Section: Dna Isolation and Mutational Analysismentioning
confidence: 99%
“…However, after a honeymoon period of response to therapy, acquired resistances can occur (21). The vast majority of cancers treated with target therapy harbor therapy-induced new genetic changes, in term of both acquisition and loss of gene alterations (22,23). Moreover, histological shift from well differentiated to poorly differentiated small cell cancer has been described as acquired resistance mechanism (23)(24)(25).…”
Section: Molecular Testingmentioning
confidence: 99%
“…The vast majority of cancers treated with target therapy harbor therapy-induced new genetic changes, in term of both acquisition and loss of gene alterations (22,23). Moreover, histological shift from well differentiated to poorly differentiated small cell cancer has been described as acquired resistance mechanism (23)(24)(25). Comprehensive molecular profiling of other more frequent lung cancer types including squamous and large cell carcinoma revealed a marked genomic complexity with less druggable alterations for the first and genetic features typical of other better differentiated carcinomas for the latter (26,27).…”
Section: Molecular Testingmentioning
confidence: 99%